AAM
NTLA icon

Azzad Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Azzad Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,496
Closed -$234K – 309
2024
Q1 		$234K Buy
8,496
+173
+2% +$4.8K 0.03% 290
2023
Q4 		$254K Buy
8,323
+571
+7% +$16.4K 0.03% 293
2023
Q3 		$245K Buy
7,752
+1,489
+24% +$57.8K 0.03% 292
2023
Q2 		$255K Buy
6,263
+454
+8% +$18.4K 0.03% 306
2023
Q1 		$217K Sell
5,809
-147
-2% -$5.76K 0.03% 307
2022
Q4 		$208K Buy
5,956
+87
+1% +$4.14K 0.03% 305
2022
Q3 		$328K Sell
5,869
-202
-3% -$12.5K 0.03% 368
2022
Q2 		$314K Buy
6,071
+590
+11% +$30K 0.03% 365
2022
Q1 		$398K Sell
5,481
-624
-10% -$52.9K 0.06% 285
2021
Q4 		$722K Buy
6,105
+150
+3% +$18.8K 0.1% 264
2021
Q3 		$799K Sell
5,955
-981
-14% -$149K 0.12% 252
2021
Q2 		$1.12M Buy
6,936
+210
+3% +$16.4K 0.17% 217
2021
Q1 		$540K Buy
+6,726
New +$451K 0.09% 271

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Azzad Asset Management's NTLA Position: Q2 2024 in Review

Azzad Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 8,496 shares — an estimated $234K sold.

Azzad Asset Management first reported a position in NTLA in Q1 2021 and held it in 13 quarters. The position peaked at $1.12M in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

  • Azzad Asset Management reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Azzad Asset Management sold 8,496 Intellia Therapeutics shares in Q2 2024, an estimated $234K.
  • Azzad Asset Management first reported a position in Intellia Therapeutics in Q1 2021 and held it in 13 quarters.
  • Azzad Asset Management's Intellia Therapeutics position peaked at $1.12M in Q2 2021.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Azzad Asset Management's 13F filing for Q2 2024, filed 30 Jul 2024.